SCHEMBL1919862

SCHEMBL1919862

COC(=O)Cc1ccccc1-c1ccc(C=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 3/20 0.46
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
DRD5 P21918 1/20 0.46
DRD3 P35462 1/20 0.46
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 3/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A3 Q01959 2/20 0.37
RXFP1 Q9HBX9 1/20 0.36
FFAR1 O14842 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
CYP1A2 P05177 1/20 0.36
HSP90AA1 P07900 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7353766 0.84 KMT2A (0.51) KMT2AKDM4ECYP4F2CYP4A11SLC6A4
SCHEMBL28321278 0.83 ACLY (0.48) ALDH1A1KMT2AMEN1CYP4F2CYP4A11
Hydrogen Sulfide SCHEMBL28029150 0.83 KMT2A (0.50) KMT2AKDM4ESLC6A4SLC6A3
SCHEMBL3858145 0.81 PTGS2 (0.48) DRD1DRD2DRD4DRD5DRD3
SCHEMBL3550978 0.81 FOLH1 (0.50) KMT2AKDM4E
SCHEMBL8266911 0.79 CYP4F2 (0.44) KMT2AKDM4ECYP4F2CYP4A11SLC6A3
SCHEMBL14159397 0.79 CYP4F2 (0.44) ALDH1A1KDM4EMAPTCYP4F2CYP4A11
SCHEMBL2557632 0.79 EPHX1 (0.43) ALDH1A1KMT2AKDM4EMEN1CYP4F2
SCHEMBL6163833 0.78 AR (0.44) HPGD
SCHEMBL14339319 0.78 KMT2A (0.40) KMT2AKDM4ECYP4F2CYP4A11SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299023-B2 Neuropeptide-2 receptor (Y-2R) agonists HOFFMANN-LA ROCHE INC. (US) 2012-10-30 US disclosed
EP-2326666-A1 NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2011-06-01 EP disclosed
WO-2010031707-A1 NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 WO disclosed
US-20100069307-A1 NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS DANHO WALEED 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069307-A1 NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS NPY2R, NPY1R, NPY4R DRD1 476/4885DRD2 271/4885DRD4 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.